Literature DB >> 1746998

The autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope.

S D Nelson1, M Stanley, C J Love, K S Coyne, S F Schaal.   

Abstract

Adenosine appears to be an important mediator of hypotension and bradycardia in certain subsets of patients with vasodepressor syncope. Adenosine receptor blockage with methylxanthines may hypothetically prevent the vasodepressor spell. We studied the chronotropic, hemodynamic, and cardiac autonomic responses to head-up tilt in patients (mean age 40.7 +/- 18.1 years) with vasodepressor syncope before and after treatment with oral theophylline. At baseline, hypotension and syncope or near syncope were induced at 11.7 +/- 2.3 minutes of 60 degrees head-up tilt in all patients. Cardiac vagal and sympathetic tone showed biphasic and directionally opposite changes during tilt. Repeat tilt during oral theophylline therapy (6-12 mg/kg/day for 14 +/- 6 days) did not provoke symptomatic hypotension in 82% of patients. During 10.7 +/- 6.1 months of follow-up, seven patients had no recurrence of vasodepressor syncope and seven patients discontinued theophylline because of adverse reactions. Low-dose theophylline prevents tilt-induced vasodepressor syncope and may prevent spontaneous vasodepressor syncope in selected patients who can tolerate theophylline.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1746998

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  9 in total

Review 1.  The role of adenosine in neurogenic syncope: much ado about something?

Authors:  I Biaggioni
Journal:  Clin Auton Res       Date:  2001-06       Impact factor: 4.435

Review 2.  Neurocardiogenic syncope: aetiology and management.

Authors:  K A Gatzoulis; P K Toutouzas
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Assessment of left ventricular volume by an ambulatory radionuclide monitoring system during head-up tilt in patients with unexplained syncope: relation to autonomic activity assessed by heart rate variability.

Authors:  H Hosaka; B Takase; K Kitamura; A Uehata; K Satomura; K Isojima; S Kosuda; S Kusano; A Kurita; F Ohsuzu
Journal:  J Nucl Cardiol       Date:  2001 Nov-Dec       Impact factor: 5.952

4.  Preliminary observations on the use of midodrine hydrochloride in the treatment of refractory neurocardiogenic syncope.

Authors:  B P Grubb; B Karas; D Kosinski; K Boehm
Journal:  J Interv Card Electrophysiol       Date:  1999-07       Impact factor: 1.900

Review 5.  Strategy for the management of vasovagal syncope.

Authors:  Daniel M Bloomfield
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 6.  Pharmacological treatment of reflex syncope.

Authors:  Horacio Kaufmann; Roy Freeman
Journal:  Clin Auton Res       Date:  2004-10       Impact factor: 4.435

7.  Role of endogenous adenosine in vasovagal syncope.

Authors:  M Sinkovec; A Grad; P Rakovec
Journal:  Clin Auton Res       Date:  2001-06       Impact factor: 4.435

8.  Syncope.

Authors:  Pamela Nerheim; Brian Olshansky
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-08

9.  Recurrent asystoles associated with vasovagal reaction during venipuncture.

Authors:  E J Cho; T H Rho; H Y Kim; C J Kim; M Y Lee; S W Jin; J C Park; J H Kim; S J Hong; K B Choi
Journal:  Korean J Intern Med       Date:  2000-12       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.